艾伯塞拉生物 ABCL
$11.88 +$0.75 (+6.74%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $11.86 -0.16%
开盘$11.56
昨收$11.13
当日区间$11.20 – $11.98
成交量2.21M
市值$3.85B
市盈率（TTM）–
股息率–
财报
财报日平均波动±6.5%近16次财报
收涨次数4 / 1625% 的概率
最佳反应+10.3%
最差反应-13.7%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q2 | 5 Aug 2026 | After Market | ±18.1% | +10.30% | 符合区间 |
| 2026/Q1 | 11 May 2026 | After Market | ±12.9% | -5.71% | 符合区间 |
| 2025/Q4 | 24 Feb 2026 | After Market | ±22.4% | -0.93% | 符合区间 |
| 2025/Q3 | 6 Nov 2025 | After Market | ±18.5% | -13.69% | 符合区间 |
| 2025/Q2 | 7 Aug 2025 | After Market | ±26.2% | +0.24% | 符合区间 |
| 2025/Q1 | 8 May 2025 | After Market | ±35.1% | +1.00% | 符合区间 |
| 2024/Q4 | 27 Feb 2025 | After Market | ±30.8% | -11.47% | 符合区间 |
| 2024/Q3 | 4 Nov 2024 | After Market | ±19.3% | -5.88% | 符合区间 |
| 2024/Q2 | 6 Aug 2024 | After Market | ±15.8% | -7.72% | 符合区间 |
| 2024/Q1 | 7 May 2024 | After Market | ±19.4% | -4.95% | 符合区间 |
| 2023/Q4 | 20 Feb 2024 | After Market | ±19.6% | -9.42% | 符合区间 |
| 2023/Q3 | 2 Nov 2023 | After Market | ±19.3% | +6.09% | 符合区间 |
| 2023/Q2 | 3 Aug 2023 | After Market | ±17.8% | -13.34% | 符合区间 |
| 2023/Q1 | 4 May 2023 | After Market | ±18.2% | -9.38% | 符合区间 |
| 2022/Q4 | 21 Feb 2023 | After Market | ±18.3% | -1.12% | 符合区间 |
| 2022/Q3 | 8 Nov 2022 | After Market | ±15.3% | -3.51% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
营收构成
2025/FY 季度
按地区
基本面
最新报告季度：Q2, ended Jun 2026
营收$4.05M-76.3% YoY
营业利润-$58.92M-28.4% YoY
净利润-$55.43M-59.6% YoY
摊薄每股收益-$0.18-50.0% YoY
自由现金流$23.79M+152.0% YoY
经营现金流$25.92M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
营业利润率-318.8%
净利率-248.8%
净资产收益率-17.3%
资产收益率-12.2%
投入资本回报率-16.4%
流动比率12.77
负债/资产比率31.5%
现金及投资$540.10M
总负债$129.95M
净现金（净负债）$410.16M
暂无评论——快来第一个聊聊 ABCL。
登录后参与讨论。